Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 32,907 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo/Control Clear all
Completed Phase 3 Interventional Results available

Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects

NCT00798967
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
teduglutide, placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
11
States / cities
La Jolla, California • Washington D.C., District of Columbia • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects

NCT05203692
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
DS-7011a, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Long Beach, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 3 Interventional

Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)

NCT00288236
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Rimonabant (SR141716), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 7, 2009 · Synced Oct 21, 2026, 5:36 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Study of Safety and Efficacy of ALT-100mAb in Participants With Moderate/Severe ARDS

NCT05938036
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome (ARDS)
Interventions
ALT-100 mAb, ALT-100 (Placebo)
Drug
Lead sponsor
Aqualung Therapeutics Corp.
Industry
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects

NCT00352911
View directory record Official record
Conditions
HIV Infections
Interventions
VGX-410 (Mifepristone), Placebo for VGX-410 (Mifepristone)
Drug
Lead sponsor
VGX Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2010 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea

NCT03471871
View directory record Official record
Conditions
Obstructive Sleep Apnea, Healthy Subjects
Interventions
Placebo, Lemborexant 10 mg, Lemborexant 25 mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
11
States / cities
Glendale, Arizona • Phoenix, Arizona • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Varenicline Safety, Tolerability, Pharmacokinetics and Pro-Cognitive Effects in Healthy Elderly Non-Smoking Subjects

NCT00694044
View directory record Official record
Conditions
Healthy, Non-Smoking
Interventions
varenicline, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 2, 2009 · Synced Oct 21, 2026, 5:36 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

NCT04497844
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Niraparib+ Abiraterone acetate fixed dose combination (FDC), Abiraterone acetate (AA), Prednisone, Placebo FDC, Placebo AA
Combination Product · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
53
States / cities
Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial of Ginseng in Diabetes

NCT00781534
View directory record Official record
Conditions
Diabetes
Interventions
Ginseng, ginsenoside RE, Placebo (sugar pill)
Drug · Dietary Supplement
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 3 Interventional Results available

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)

NCT04568434
View directory record Official record
Conditions
Familial Chylomicronemia Syndrome
Interventions
Olezarsen, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
17
States / cities
Huntington Beach, California • San Francisco, California • Boca Raton, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery

NCT03856164
View directory record Official record
Conditions
Post Partum Hemorrhage, Fibrinolysis; Hemorrhage, Blood Loss
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 21, 2026, 5:36 AM EDT
Withdrawn Phase 4 Interventional

The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 Insulin

NCT02597309
View directory record Official record
Conditions
Diabetes, Obesity
Interventions
Canagliflozin
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults

NCT02365532
View directory record Official record
Conditions
Long QT Syndrome
Interventions
GS-6615, Placebo to match GS-6615, Placebo to match dofetilide, Dofetilide
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 2 Interventional

A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain

NCT00394563
View directory record Official record
Conditions
Osteoarthritis
Interventions
RN624 (PF-04383119), placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 75 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2009 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia

NCT00784875
View directory record Official record
Conditions
Primary Insomnia, Secondary Insomnia
Interventions
LY2624803, Placebo, zolpidem
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
49
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2012 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD

NCT04542057
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Ensifentrine, Placebo
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
77
States / cities
Alabaster, Alabama • Andalusia, Alabama • Jasper, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 21, 2026, 5:36 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

NCT07284901
View directory record Official record
Conditions
Obesity With Diabetes, Overweight With Diabetes
Interventions
Ribupatide, Placebo
Drug
Lead sponsor
Kailera
Industry
Eligibility
18 Years and older
Enrollment
1,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
62
States / cities
Cullman, Alabama • Phoenix, Arizona • Sun City, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 5:36 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults.

NCT05035212
View directory record Official record
Conditions
Lower Respiratory Tract Illness
Interventions
RSVpreF, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
60 Years and older
Enrollment
38,861 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
176
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 21, 2026, 5:36 AM EDT
Active, not recruiting Phase 3 Interventional

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

NCT06894212
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856, Placebo
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
35
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

8 Weeks of L-CIT Supplementation and LIRET on Vascular Function in Hypertensive Postmenopausal Women

NCT05227781
View directory record Official record
Conditions
Hypertension, Menopause
Interventions
L-Citrulline, Placebo
Dietary Supplement
Lead sponsor
Texas Tech University
Other
Eligibility
50 Years to 75 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 21, 2026, 5:36 AM EDT
Terminated Phase 1 Interventional

AMG 761 in Adults With Asthma

NCT01514981
View directory record Official record
Conditions
Asthma
Interventions
AMG 761, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Denver, Colorado • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 3 Interventional Results available

Effect of Maraviroc on Endothelial Function in HIV-Infected Patients

NCT00844519
View directory record Official record
Conditions
HIV Infection, Cardiovascular Disease, Inflammation, HIV Infections
Interventions
Maraviroc, placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 21, 2026, 5:36 AM EDT
Not yet recruiting Phase 2 Interventional

A Ph2, Colchicine For Inflammatory Carotid Injury And Disease Evolution After Radiotherapy

NCT07856719
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Colchicine, Placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2034
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 5:36 AM EDT
Completed Phase 2 Interventional Results available

Cannabidiol Effects on Craving and Relapse Prevention in Opioid Use Disorder

NCT03787628
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Cannabidiol (CBD) 600 mg, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tarzana, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 21, 2026, 5:36 AM EDT